Tower Research Capital (TRC)’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $18.6K | Buy |
2,103
+890
| +73% | +$7.87K | ﹤0.01% | 3726 |
|
|
2025
Q1 | $13.1K | Buy |
1,213
+238
| +24% | +$2.56K | ﹤0.01% | 3401 |
|
|
2024
Q4 | $12.5K | Buy |
975
+562
| +136% | +$7.19K | ﹤0.01% | 3613 |
|
|
2024
Q3 | $11.4K | Sell |
413
-830
| -67% | -$22.9K | ﹤0.01% | 3667 |
|
|
2024
Q2 | $36K | Buy |
1,243
+1,042
| +518% | +$30.2K | ﹤0.01% | 3351 |
|
|
2024
Q1 | $8.95K | Sell |
201
-1,451
| -88% | -$64.6K | ﹤0.01% | 3925 |
|
|
2023
Q4 | $64.1K | Buy |
1,652
+193
| +13% | +$7.49K | ﹤0.01% | 2966 |
|
|
2023
Q3 | $42.9K | Buy |
1,459
+1,275
| +693% | +$37.5K | ﹤0.01% | 2682 |
|
|
2023
Q2 | $11.7K | Sell |
184
-350
| -66% | -$22.2K | ﹤0.01% | 3924 |
|
|
2023
Q1 | $25K | Buy |
534
+382
| +251% | +$17.9K | ﹤0.01% | 3207 |
|
|
2022
Q4 | $10K | Sell |
152
-275
| -64% | -$18.1K | ﹤0.01% | 4030 |
|
|
2022
Q3 | $63K | Buy |
427
+31
| +8% | +$4.57K | ﹤0.01% | 2957 |
|
|
2022
Q2 | $51K | Sell |
396
-37
| -9% | -$4.77K | ﹤0.01% | 2861 |
|
|
2022
Q1 | $44K | Sell |
433
-9
| -2% | -$915 | ﹤0.01% | 2834 |
|
|
2021
Q4 | $68K | Buy |
442
+318
| +256% | +$48.9K | ﹤0.01% | 2516 |
|
|
2021
Q3 | $37K | Buy |
+124
| New | +$37K | ﹤0.01% | 3199 |
|